The role of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus

Sayenko Ya., Nagybyn V., Mankovsky B.

Abstract

Modern pharmacology offers a wide range of antidiabetic medications. Among them, very important medications are those that affect the activity of incretins (groups of metabolic hormone-like substances that are released after eating and perform the function of reducing the level of glucose in the blood). This group includes two main classes of substances with a proven therapeutic effect in type 2 diabetes: agonists of incretin receptors, primarily glucagon-like peptide 1, and inhibitors of incretin-destroying enzymes, the main representatives of which are dipeptidyl-peptidase inhibitors 4 (DPP-4). Many studies have convincingly demonstrated that DPP-4 inhibitors have, in addition to antidiabetic, endothelioprotective, capillary stabilizing effects and other spectrums of therapeutic activity, which, by the way, are not only related to mechanisms mediated by glucagon-like peptide-1. In the latest joint consensus of the American Diabetes Association and the European Association for the Study of Diabetes on the management of hyperglycemia in patients with type 2 diabetes, DPP-4 inhibitors are a potent and safe group of oral glucose-lowering drugs that can be used in both patients without cardiovascular and renal pathology, as well as as part of combined therapy with agonists of glucagon-like peptide-1 and inhibitors of sodium-glucose cotransporter 2.

Key words: type 2 diabetes, dipeptidyl-peptidase inhibitors 4, agonists glucagon-like peptide-1, inhibitors of sodium-glucose cotransporter 2.

References

1. Peng Gao, Li Li, Xiao Wei, et al. Activation of Transient Receptor Potential Channel Vanilloid 4 by DPP-4 (Dipeptidyl Peptidase-4) Inhibitor Vildagliptin Protects Against Diabetic Endothelial Dysfunction // Hypertension. 2020;75:00-00. DOI: 10.1161/HYPERTENSIONAHA.119.13778.
   Alessandra Schiappacassa, Priscila A. Maranhão, Maria das Graças Coelho de Souza, et al. Acute Effects of Metformin and Vildagliptin after a Lipid-Rich Meal on Postprandial Microvascular Reactivity in Patients with Type 2 Diabetes and Obesity: A Randomized Trial. // J. Clin. Med. 2020, 9, 3228; doi:10.3390/jcm9103228.
2. Dong-Yi Chen, Yan-Rong Li, Chun-Tai Mao, et al. Cardio- vascular outcomes of vildagliptin in patients with type 2 diabetes mellitus after acute coronary syndrome or acute ischemic stroke. // J Diabetes Investig. 2020;11(1):110-124. doi: 10.1111/jdi.13078.
3. Yosuke Ishida, Hiroki Murayama, Yohei Shinfukuб et al. Cardiovascular safety and effectiveness of vildagliptin in patients with type 2 diabetes mellitus: a 3-year, large-scale post-marketing surveillance in Japan. // Expert Opinion on Drug Safety, 2020, DOI: 10.1080/14740338.2020.1740679
4. John J.V. McMurray, Piotr Ponikowski, Geremia B. Bolli, et al. Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure;(NCT00894868) (J Am Coll Cardiol HF 2017.
5. Salah Shelbaya & Sameh Rakha (2017): Effectiveness and safety of vildagliptin and vildagliptin add-on to metfor- min in real-world settings in Egypt – results from the GUARD study, Current Medical Research and Opinion, DOI: 10.1080/03007995.2016.1277199.
6. Ibrahim El Ebrashy, Nabil El Kafrawy, Rana Raouf, Diana Yousry. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study. // Diabetes research and clinical practice, 162, (2020), 108042. https://doi.org/10.1016/j.diabres.2020.108042
7. David R Matthews, Päivi M Paldánius, Pieter Proot, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, doubleblind trial. // Lancet. 2019;394(10208):1519-1529. doi: 10.1016/S0140-6736(19)32131-2.
8. Matthews DR, Paldonius PM, Proot P, et al. Lancet 2019; 394(10208): 1519-1529 doi: 10.1016/S0140-6736 (19)32131-2.
9. Laiteerapong N, Ham SA, Gao Y, et al. Diabetes Care 2019; 42(3): 416-426. https://doi.org/10.2337/dc17-1144.
10. Laiteerapong N, Karter AJ, Moffet HH, et al. J Diabetes Complications 2017; 31: 94-100. doi: 10.1016/j.jdiacomp.
    07.023.
11. David R Matthews, Päivi M Paldánius, Pieter Proot, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. // Lancet. 2019;394(10208):1519-1529. doi: 10.1016/S0140- 6736(19)32131-2.
12. Ahrén B, Foley JE. The vildagliptin experience – 25 years since. The Initiation Of The Novartis Foley Je, Ahren B. The Vildagliptin Experience – 25 Years Since The Initiation Of The Novartis Glucagon-Like Peptide-1 Based Therapy Programme And 10 Years Since The First Vildagliptin Reg- istration. Eur Endocrinol. 2017;13(2):56-61.
13. L., SadlerB.M., SaboR. et al. The absolute oral bioavailability and population-based pharmacokinetic modelling of a novel dipeptidylpeptidase IV inhibitor, vildagliptin, in healthy volunteers// Clin. Pharmacokinet.– 2007.– 46.– P.787-802.
14. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetesd2021 Diabetes Care 2021;44(Suppl. 1):S111–S124 | https://doi.org/10.2337/ dc21-S009
15. Phung OJ, Sobieraj DM, Engel SS, Rajpathak SN. Early combination therapy for the treatment of type 2 diabetes mellitus: systematic review and meta-analysis. Diabetes Obes Metab 2014; 16: 410-17.